Context Therapeutics (CNTX) to Release Quarterly Earnings on Wednesday

Key Points

• Context Therapeutics will report Q1 2026 results before the market opens on May 6, with analysts forecasting ($0.12) EPS; an earnings call is scheduled for May 8 at 4:00 PM ET and the company missed the prior quarter (reported ($0.14) vs. ($0.11) estimate).
• The stock trades around $2.51 with a market cap of $230.6M, a negative P/E, 50‑day/200‑day moving averages of $2.62 and $1.87, and a 1‑year range of $0.49–$3.62.
• Several large funds (Millennium, Marshall Wace, Renaissance, Vanguard, Citadel) have recently increased or initiated positions—institutions own 14.03%—and analysts show a consensus "Moderate Buy" with an average price target of $6.60 (1 Strong Buy, 6 Buy, 1 Sell).

Context Therapeutics (NASDAQ:CNTX - Get Free Report) will likely be issuing its Q1 2026 results before the market opens on Wednesday, May 6th. Analysts expect the company to announce earnings of ($0.12) per share for the quarter. Parties may visit the the company's upcoming Q1 2026 earning results page for the latest details on the call scheduled for Friday, May 8, 2026 at 4:00 PM ET.

Context Therapeutics (NASDAQ:CNTX - Get Free Report) last issued its quarterly earnings results on Monday, March 23rd. The company reported ($0.14) earnings per share for the quarter, missing analysts' consensus estimates of ($0.11) by ($0.03). On average, analysts expect Context Therapeutics to post $0 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Context Therapeutics Price Performance

Shares of NASDAQ:CNTX opened at $2.51 on Wednesday. The stock has a market cap of $230.62 million, a P/E ratio of -6.61 and a beta of 1.82. The firm has a fifty day moving average price of $2.62 and a 200 day moving average price of $1.87. Context Therapeutics has a 1-year low of $0.49 and a 1-year high of $3.62.

Hedge Funds Weigh In On Context Therapeutics

A number of large investors have recently made changes to their positions in CNTX. Millennium Management LLC purchased a new position in shares of Context Therapeutics in the 4th quarter valued at about $3,824,000. Marshall Wace LLP increased its holdings in Context Therapeutics by 7,153.7% during the 4th quarter. Marshall Wace LLP now owns 2,593,198 shares of the company's stock valued at $3,812,000 after acquiring an additional 2,557,448 shares in the last quarter. Renaissance Technologies LLC increased its holdings in Context Therapeutics by 58.8% during the 4th quarter. Renaissance Technologies LLC now owns 508,329 shares of the company's stock valued at $747,000 after acquiring an additional 188,202 shares in the last quarter. Vanguard Group Inc. increased its holdings in Context Therapeutics by 4.0% during the 3rd quarter. Vanguard Group Inc. now owns 3,495,031 shares of the company's stock valued at $3,387,000 after acquiring an additional 134,449 shares in the last quarter. Finally, Citadel Advisors LLC purchased a new position in Context Therapeutics during the 3rd quarter valued at about $100,000. Hedge funds and other institutional investors own 14.03% of the company's stock.

Wall Street Analyst Weigh In

CNTX has been the subject of a number of recent research reports. Weiss Ratings reiterated a "sell (d-)" rating on shares of Context Therapeutics in a research note on Monday, April 20th. Wall Street Zen downgraded shares of Context Therapeutics from a "hold" rating to a "sell" rating in a research report on Sunday, March 29th. D. Boral Capital restated a "buy" rating and set a $9.00 price objective on shares of Context Therapeutics in a research report on Tuesday, March 24th. Lifesci Capital upgraded shares of Context Therapeutics to a "strong-buy" rating in a research report on Monday, February 23rd. Finally, Piper Sandler upped their price objective on shares of Context Therapeutics from $4.00 to $7.00 and gave the stock an "overweight" rating in a research report on Tuesday, March 24th. One investment analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average price target of $6.60.

About Context Therapeutics

Context Therapeutics NASDAQ: CNTX is a clinical-stage biopharmaceutical company focused on the discovery and development of precision therapies for genetically defined patient populations in oncology. The company's research model centers on identifying novel targets and designing small-molecule and biologic candidates that address key drivers of tumor growth and resistance. Context Therapeutics leverages a biomarker-driven approach to maximize the probability of clinical response, tailoring its development programs to specific molecular subgroups within solid tumors.

With a pipeline advancing through early clinical trials, Context Therapeutics emphasizes strategic collaborations and academic partnerships to accelerate the translation of laboratory findings into patient-focused studies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.